Navigation Links
University of Maryland School of Medicine finds depression stems from miscommunication between brain cells
Date:3/18/2013

A new study from the University of Maryland School of Medicine suggests that depression results from a disturbance in the ability of brain cells to communicate with each other. The study indicates a major shift in our understanding of how depression is caused and how it should be treated. Instead of focusing on the levels of hormone-like chemicals in the brain, such as serotonin, the scientists found that the transmission of excitatory signals between cells becomes abnormal in depression. The research, by senior author Scott M. Thompson, Ph.D., Professor and Interim Chair of the Department of Physiology at the University of Maryland School of Medicine, was published online in the March 17 issue of Nature Neuroscience.

According to the Centers for Disease Control and Prevention, between 2005 and 2008, approximately one in 10 Americans were treated for depression, with women more than twice as likely as men to become depressed. The most common antidepressant medications, such as Prozac, Zoloft and Celexa, work by preventing brain cells from absorbing serotonin, resulting in an increase in its concentration in the brain. Unfortunately, these medications are effective in only about half of patients. Because elevation of serotonin makes some depressed patients feel better, it has been thought for over 50 years that the cause of depression must therefore be an insufficient level of serotonin. The new University of Maryland study challenges that long-standing explanation.

"Dr. Thompson's groundbreaking research could alter the field of psychiatric medicine, changing how we understand the crippling public health problem of depression and other mental illness," says E. Albert Reece, M.D., Ph.D., M.B.A., Vice President for Medical Affairs at the University of Maryland and John Z. and Akiko K. Bowers Distinguished Professor and Dean at the University of Maryland School of Medicine. "This is the type of cutting-edge science that we strive toward a
'/>"/>

Contact: Karen Robinson
karobinson@som.umaryland.edu
410-706-7590
University of Maryland Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Columbia University Medical Center/NY-Presbyterian experts at AAN
2. Eurofins MWG Operon and Queen Mary, University Of London commence genome sequencing analysis of Ash
3. University of Maryland School of Medicine discovers adaptations to explain strategies for survival on Mars
4. University of Miami geologists to address the mystery of an evolution gap in reef corals
5. University of Illinois researchers develop AFM-IR for nanometer scale chemical identification
6. University of Alberta researchers bake a better loaf of bread
7. UC Berkeley, UCSF and Stanford join forces to help commercialize university innovations
8. University of Colorado and Orphan Technologies sign agreement
9. Brown University researchers build robotic bat wing
10. Wayne State University researchers techniques enable more, faster testing of biological liquids
11. University of Arizona Engineering College pursues water technology innovation cluster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Research and Markets( ... "Natural Language Processing Market by Type (Rule-Based, ... & Image Recognition) - Worldwide Forecast to 2020" ... key vendors occupying the market are 3M, Apple, ... NetBase Solutions, SAS Institute Inc., Verint Systems among ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... drug-delivery devices and fire extinguishers to improve spray technologies, ... of Swedish Biomimetics 3000 Ltd, in Aprils Physics World. ... Asia, is remarkable in that it can fire a ... predators such as birds and frogs. While the ...
... of changes to the microbes that live in them just ... by global warming, according to scientists speaking today (Wednesday 2 ... being held this week at the Edinburgh International Conference Centre. ... knife edge. Corals in coral reefs, which are made up ...
... SPRING HARBOR, N.Y. (Tuesday, April 1, 2008) ... processes in the mouse used to be a monumental ... search, making it effective for even the smallest laboratories. ... Protocols ( www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for ...
Cached Biology News:The bombardier beetle, power venom and spray technologies 2Coral reefs and climate change: Microbes could be the key to coral death 2Coral reefs and climate change: Microbes could be the key to coral death 3Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas ... Bi-Gel, a nighttime-specific product that targets fat cells for extreme contouring action. During ... enter fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks ...
(Date:7/28/2015)... July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines to ... Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a recently-formed ... ( c. £76.5m), gross, from blue chip institutional investors ...
(Date:7/28/2015)... , July 28, 2015 Seahorse Bioscience, ... metabolism, is the provider of XF Technology which ... disease research areas. As the links between mitochondrial ... cell metabolism is escalating rapidly.   ... the Nature Publishing Group (NPG) featuring XF Technology, ...
(Date:7/28/2015)... , July 28, 2015 Deerfield Management Company, ... Innovations Fund, L.P., which will invest in groundbreaking advancements ... genetic diseases, cancer, and orphan diseases. The venture capital ... how therapeutics are developed and improve the way healthcare ... of the largest healthcare-focused venture funds in the sector, ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3
... Insmed Incorporated (Nasdaq CM: INSM), a ... J.D. has been appointed to the newly created position ... effective as of July 18, 2011.  Ms. Drucker, who ... Executive Officer of Insmed, will provide strategic legal and ...
... , 90% , Reduction ... Compared With Normal Disease Progression SEEK, a ... completed a Phase Ib/II,clinical trial of its HIV-v vaccine ... in HIV-infected,people compared with the placebo group, after just a single ...
... Champions Oncology, Inc., formerly Champions Biotechnology, Inc., (OTC: CSBR): ... 2011 Revenue growth of 41% to $6.9 million ... net loss of $0.7 million* Net loss of ... Cash of $10.5 million at year end ...
Cached Biology Technology:Andrea Drucker Joins Insmed as General Counsel 2Andrea Drucker Joins Insmed as General Counsel 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6Champions Oncology Reports Full Year 2011 Financial Results 2Champions Oncology Reports Full Year 2011 Financial Results 3Champions Oncology Reports Full Year 2011 Financial Results 4Champions Oncology Reports Full Year 2011 Financial Results 5Champions Oncology Reports Full Year 2011 Financial Results 6